SELLAS Life Sciences Group, Inc.

8-K · tm2616601d1_8k.htm iXBRL

0001390478

 2026-06-02
 2026-06-02

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 WASHINGTON, D.C. 20549

  

  

  

 FORM 8-K

  

  

  

 CURRENT REPORT

 PURSUANT TO SECTION 13 OR 15(d) OF THE

 SECURITIES EXCHANGE ACT OF 1934

  

 Date of report (Date of earliest event
reported): June 2, 2026

  

  

  

 SELLAS
Life Sciences Group, Inc.

 (Exact name of registrant as specified in its charter)

  

  

  

 Delaware
  
 001-33958
  
 20-8099512

 (State or other jurisdiction of
 incorporation or organization)
  
 (Commission

File Number)
  
 (I.R.S. Employer

Identification No.)

  
  
  
  
  

  
  
 7 Times Square , Suite 2503
 New York , NY 10036
  
  

  
  
 (Address of Principal Executive
 Offices) (Zip Code)
  
  

  
  
  
  
  

 Registrant’s
 telephone number, including area code: ( 646 ) 200-5278

  

  

   

 Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

  

 ¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

 ¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

 ¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities registered pursuant to Section 12(b) of the Act:

  

 Title
 of each class
 Trading

 symbol(s)
 Name of each exchange
 on which

 registered

 Common Stock, $0.0001 par value per share
 SLS
 The Nasdaq Stock Market LLC

  

 Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).

  

 Emerging growth company ¨

  

 If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨

  

  

  

  

  

 Item 8.01 Other Events

  

 As previously reported, as of March 31, 2026,
SELLAS Life Sciences Group, Inc. (the “Company”) had $107.1 million of cash and cash equivalents.

  

 Subsequent to March 31, 2026, in April and May
2026, the Company received approximately $28.7 million in proceeds from the exercise of common stock warrants.

  

 As of June 2, 2026, the Company had 196,632,574
shares of common stock outstanding.

  

 Item 9.01. Financial Statements and Exhibits.

  

 (d)       Exhibits

  

 Exhibit Number
  
 Description

 104
  
 Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 3

  

  

 SIGNATURES

  

 Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

   

  
 SELLAS Life Sciences Group, Inc.

  
  
  
  

 Date:
 June 2, 2026
 By:
 /s/ John T. Burns

  
  
  
 Name:
 John T. Burns

  
  
  
 Title:
 Senior Vice President, Chief Financial Officer

  

 4